Vaginal dryness

What it is

Vaginal dryness affects an estimated 40–60% of postmenopausal women, yet remains one of the most underreported and undertreated conditions in women's health. It occurs when declining estrogen causes vaginal tissues to thin, lose elasticity, and produce less natural lubrication — a process that worsens progressively without treatment, unlike hot flashes, which often ease over time.

Clinically, vaginal dryness is the hallmark symptom of genitourinary syndrome of menopause (GSM), the current preferred term that replaced the older labels atrophic vaginitis and vulvovaginal atrophy (VVA). GSM encompasses the full spectrum of vaginal and lower urinary tract changes driven by estrogen loss after menopause. The condition is not confined to older women: it can occur at any age when estrogen levels fall, including during breastfeeding, after surgical removal of the ovaries, or following certain cancer treatments.

For Canadian patients, GSM is a recognized clinical priority. The Society of Obstetricians and Gynaecologists of Canada (SOGC) has issued guidance on menopausal hormone therapy that addresses genitourinary symptoms, and local estrogen products are available through most provincial drug benefit programs, though coverage criteria vary by province.

Causes and mechanism

Estrogen maintains the thickness, glycogen content, and blood supply of vaginal epithelium. It also supports the lactobacilli that keep vaginal pH below 4.5. When estrogen falls, the epithelium thins, glycogen drops, lactobacilli decline, and pH rises — creating dryness, fragility, and increased infection risk.

Common causes of estrogen deficiency leading to vaginal dryness:

Cause	Typical age of onset	Estrogen loss pattern
Natural menopause	51 (Canadian average)	Gradual over perimenopause
Surgical menopause (bilateral oophorectomy)	Any age	Abrupt and complete
Premature ovarian insufficiency (POI)	Before 40	Variable, often permanent
Breastfeeding	Reproductive years	Temporary; prolactin-mediated
Chemotherapy / pelvic radiation	Any age	Partial to complete
Aromatase inhibitors (breast cancer therapy)	Varies	Sustained suppression

Other contributing factors include some combined oral contraceptives (which can reduce local androgen levels), antihistamines, certain antidepressants, Sjögren's syndrome, and insufficient sexual arousal — which reduces transudation independent of hormone levels.

Symptoms and diagnosis

Symptoms reflect the structural changes in vaginal and periurethral tissue:

• Persistent internal dryness or a sandpaper-like friction sensation
• Vaginal itching, burning, or irritation
• Dyspareunia (pain during or after intercourse), ranging from mild to severe
• Post-coital spotting from fragile epithelium
• A sense of vaginal tightness or narrowing
• Increased frequency of vaginal infections and changes in discharge
• Urinary urgency, frequency, and recurrent urinary tract infections (the urethra and bladder trigone are also estrogen-sensitive)

Diagnosis is clinical. A clinician will confirm the hormonal context (menopausal status, breastfeeding, medications), perform a pelvic examination looking for pale, smooth, thin mucosa, and may test vaginal pH — a reading above 5.0 supports the diagnosis, compared with the normal premenopausal range below 4.5. Serum FSH and estradiol can confirm hormonal status when the clinical picture is unclear. A vaginal swab rules out concurrent infection when discharge is present.

Treatment options

Vaginal dryness responds well to treatment. Most women experience meaningful improvement with the right approach.

Non-hormonal options (suitable for all women, including those with hormone-sensitive cancers):

• Vaginal moisturizers (e.g., Replens, Hyalofemme): used 2–3 times per week, not only during sex, to maintain baseline hydration and restore acidic pH over time.
• Vaginal lubricants: water-based or silicone-based products used at the time of sexual activity to reduce friction. Avoid oil-based products with latex condoms.
• Regular sexual activity or pelvic floor physiotherapy: maintains tissue perfusion and vaginal calibre.

Local estrogen therapy (first-line medical treatment): Low-dose vaginal estrogen — available as cream, pessary/tablet, or ring — delivers estrogen directly to vaginal tissue with minimal systemic absorption. It restores epithelial thickness, natural lubrication, and acidic pH. Ongoing use is needed to sustain benefit. Local estrogen is considered safe for the majority of women, including many who have contraindications to systemic hormone therapy, though the decision requires individualized clinical assessment.

Other hormonal and receptor-targeted options:

• Vaginal DHEA (prasterone / Intrarosa): a locally applied suppository that converts to both estrogen and testosterone within vaginal tissue. Approved in Canada and effective for both vaginal and sexual symptoms.
• Ospemifene (Osphena): an oral selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in vaginal tissue. An option for women who prefer not to use vaginal preparations.
• Systemic menopausal hormone therapy (MHT): appropriate when vaginal dryness coexists with vasomotor or other systemic menopausal symptoms. Some women on systemic MHT still benefit from adding local vaginal therapy for optimal genitourinary effect.

For women with cancer treatment-related atrophy, non-hormonal options and vaginal DHEA are typically the first approach when estrogen is contraindicated. Oncology input is essential before initiating any hormonal product in this group.

When to see a clinician in Canada

Book an appointment with your family physician, nurse practitioner, or gynaecologist if you are experiencing vaginal dryness, burning, or discomfort that affects daily life; pain during or after intercourse; recurrent vaginal or urinary tract infections; or post-coital spotting.

These symptoms are common but not inevitable, and they do not resolve on their own. Canadian patients can also access virtual menopause care through platforms such as Felix, Cleo, Maple, and others, which can prescribe local estrogen and other treatments without requiring an in-person visit. Coverage for vaginal estrogen and prasterone varies by province — check your provincial formulary or ask your pharmacist, as some products require special authorization.

Limitations and open questions

Research is still emerging on the long-term safety of low-dose vaginal estrogen in women with hormone receptor-positive breast cancer, particularly those on aromatase inhibitors. Current evidence suggests systemic absorption is minimal, but most oncology guidelines recommend non-hormonal options first in this group, and individualized oncology review is standard practice. Health Canada has not issued a standalone GSM-specific guideline; Canadian clinicians rely primarily on SOGC menopause guidance and international society statements. The optimal duration of treatment, the comparative effectiveness of newer energy-based devices (laser, radiofrequency) versus established pharmacological options, and the role of androgens in GSM management all remain active areas of investigation. Patients should be cautious about energy-based vaginal treatments marketed outside regulated clinical settings, as the evidence base is not yet sufficient to support routine use.